U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
SINGAPORE, Jan. 04, 2018 -- ASLAN Pharmaceuticals (ASLAN, 6497.TT), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and orphan indications in the United States and Europe, today announced that Carl Firth, Ph.D., Chief Executive Officer, will present an overview of the company at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 10:30 a.m. PT (January 11, 2:30 a.m. SGT) at the Westin St. Francis Hotel in San Francisco.
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (ASLAN, 6497.TT) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. ASLAN targets diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Led by a senior management team with extensive experience in global and regional development and commercialization, ASLAN is headquartered in Singapore and has offices in Taiwan and China. ASLAN’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. ASLAN’s partners include Array BioPharma, Bristol-Myers Squibb, Almirall and CSL. For additional information please visit www.aslanpharma.com.
Media and IR contacts
Chris Fang
ASLAN Pharmaceuticals
Tel: +886 2 2758 3333
E-mail: [email protected]
Emma Thompson / Stephanie Tan
Spurwing Communications
Tel: +65 6340 7287
Email: [email protected]
Robert H. Uhl
Westwicke Partners
Tel: +1 858 356 5932
Email: [email protected]
